董事会于近日收到独立董事段朝晖先生提交的书面辞职报告，段朝晖先生 因个人工作原因申请辞去公司第五届董事会独立董事职务，同时辞去董事会薪 酬与考核委员会主任委员、董事会战略委员会委员职务，其辞职后将不再担任 公司任何职务。段朝晖先生上述职务原定任期为自第五届董事会选举完成之日 至 2027 年 6 月 13 日。 鉴于段朝晖先生的离任将导致薪酬与考核委员会中独立董事所占比例不符 合法律法规和公司章程的规定，根据《公司法》《深圳证券交易所上市公司自律 监管指引第 2 号—创业板上市公司规范运作》和《公司章程》的有关规定，段 朝晖先生的辞职将在股东会选出新任独立董事后生效，在此之前段朝晖先生将 继续履职。 | 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2026-003 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 关于补选公司第五届董事会独立董事和选举非独立董 事并调整董事会专门委员会委员的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 广州万孚生物技术 ...

北京市君合（广州）律师事务所 关于 广州万孚生物技术股份有限公司 2026 年第二次临时股东会的 法律意见书 二零二六年一月 | 北京总部 | 电话: | (86-10) 8519-1300 | 上海分所 | 电话: | (86-21) 5298-5488 | 广州分所 | 电话: (86-20) 2805-9088 | 深圳分所 | 电话: (86-755) 2939-5288 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 传真: | (86-10) 8519-1350 | | 传真: | (86-21) 5298-5492 | | 传真: (86-20) 2805-9099 | | 传真: (86-755) 2939-5289 | | 杭州分所 | 电话: | (86-571) 2689-8188 | 成都分所 | 电话: | (86-28) 6739-8000 | 西安分所 | 电话: (86-29) 8550-9666 | 青岛分所 | 电话: (86-532) 6869-5000 | | | 传真: | (86 ...

| 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2026-009 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 2026 年第二次临时股东会会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会无增加、变更提案的情况。 2、本次股东会以现场投票和网络投票相结合的表决方式。 3、本次股东会未涉及变更前次股东会决议的情形。 4、中小投资者是指除上市公司董事、高级管理人员以及单独或者合计持有 公司 5%以上股份的股东以外的其他股东。 一、股东会的召开和出席情况 广州万孚生物技术股份有限公司（以下简称"公司"）2026 年第二次临时股 东会于 2026 年 1 月 23 日 14:00 在公司会议室召开。本次股东会由公司第五届董 事会召集，第五届董事会第二十次会议审议通过了召开本次临时股东会的议案。 会议通知已于 2026 年 1 月 7 日在中国证监会指定的信息披露网站公告。本次股 东会由公司董事会召集，董事长王继华女士主持，公 ...

Core Insights - The company focuses on innovation as a driving force for business development and is leveraging AI's transformative impact on healthcare, particularly in laboratory diagnostics and digital pathology [2][3] - The company plans to enhance its AI investments through mergers and acquisitions, as well as a combination of B2B and B2C strategies, aiming to create a valuable ecosystem in the AI healthcare sector [2][3] Group 1: Business Strategy and AI Integration - Since its listing in 2015, the company has been integrating AI into its operations, particularly in the digital pathology sector, and has established a leadership position in ultrasound imaging [2] - The company has developed a multi-modal diagnostic framework that includes imaging, pathology, and laboratory diagnostics, enhancing its brand influence and operational efficiency through AI applications [2] - The company aims to achieve more regulatory approvals and breakthroughs in its business model to become a leading player in the domestic AI healthcare market [3] Group 2: Financial Outlook and Performance - The company anticipates a decline in its profit statement for 2025 due to strategic adjustments, including the divestment of risk assets and a focus on improving operational quality [3] - Despite the expected downturn in 2025, the company is optimistic about a recovery in domestic business in 2026, supported by a low base from the previous year, and has positive growth expectations for its overseas operations [3] - The company has launched the "Wanfubio Smart Inspection" AI platform, which features multiple AI applications for various medical scenarios, contributing to growth in the consumer segment through its health app [3]

Core Insights - Wanfu Bio has established an AI medical ecosystem since 2018, focusing on "mergers and acquisitions + hospital end + consumer end" to become a leading player in China's AI medical field [1][2] Group 1: Investment and Partnerships - Wanfu Bio's investment in Saiweisen Medical Technology led to the acquisition of China's first Class III medical device registration for cervical cancer cell digital pathology diagnostic software, expected to be operational by February 2025 [1] - The company also invested in Shenzhen Shengqiang Technology, which aims to create intelligent pathology solutions through hardware and software integration, enhancing the digital workflow in hospital pathology departments [1] - Medical technology company Yizhun Intelligent, backed by Zhongfu Yide Industrial Fund, has received the first and second Class III certifications for breast X-ray and thyroid nodule ultrasound AI detection software, respectively [1] Group 2: Business Development and Innovations - Wanfu Bio has launched the "Wanfu Smart Inspection" AI platform for hospitals, featuring multiple AI applications in various medical scenarios, including coagulation diseases and tumors [2] - The company has introduced the Wanfu Health mini-program for consumers, which uses AI to automatically identify results from respiratory, digestive, and blood infectious disease tests, supporting personal health record creation [2] - Future plans include enhancing multi-modal and multi-omics development in diagnostics, leveraging years of experience in laboratory testing to improve grassroots testing capabilities in collaboration with its invested companies [2]

Core Viewpoint - The company is strategically enhancing its investment in the AI medical field through mergers and acquisitions, as well as a combination of B2B and B2C approaches, aiming to develop a robust AI ecosystem that provides valuable medical tools and products [1] Group 1: AI Medical Strategy - Since 2018, the company has proactively positioned itself in the AI medical sector by implementing a "mergers + hospital + C-end" strategy to build a comprehensive AI medical ecosystem [2] - The company has successfully integrated three companies—Saiweisen Medical Technology, Shengqiang Technology, and Yizhun Intelligent—into its ecosystem, each excelling in imaging, pathology, and laboratory diagnostics [2] - Saiweisen Medical Technology received the first domestic Class III medical device registration for cervical cancer cell digital pathology image-assisted diagnostic software in February 2025, highlighting its leading position in the pathology AI field [2] Group 2: Business Growth and Future Outlook - The company's overseas business is showing strong growth, particularly in the emergency scene and the U.S. market for respiratory triad testing products, which is expected to significantly boost overseas revenue by 2026 [2] - The company is committed to innovation as a core driver and plans to continue increasing investments in the AI medical field, focusing on a multi-modal diagnostic architecture that combines imaging, pathology, and laboratory diagnostics [3] - Despite a strategic adjustment in 2025 that temporarily impacted profit margins, the company anticipates a strong recovery in domestic business growth in 2026, supported by a low base from 2025 and positive expectations for overseas business growth [3]

Core Viewpoint - Wanfu Biological experienced a stock price increase of 12.81% year-to-date, with a notable rise of 4.11% in the last five trading days, indicating positive market sentiment towards the company [1]. Financial Performance - For the period from January to September 2025, Wanfu Biological reported a revenue of 1.69 billion yuan, a year-on-year decrease of 22.52%. The net profit attributable to shareholders was 134 million yuan, down 69.32% compared to the previous year [2]. - Cumulative cash dividends since the company's A-share listing amount to 1.213 billion yuan, with 601 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Wanfu Biological was 42,400, a decrease of 5.59% from the previous period. The average number of circulating shares per shareholder increased by 5.94% to 10,160 shares [2]. - Among the top ten circulating shareholders, Huabao Zhongzheng Medical ETF held 8.1927 million shares, a reduction of 1.3623 million shares from the previous period. The Southern Zhongzheng 1000 ETF held 2.6442 million shares, down by 20,900 shares [3]. Business Overview - Wanfu Biological, established on November 13, 1992, and listed on June 30, 2015, specializes in the research, production, and sales of rapid diagnostic reagents and instruments related to point-of-care testing (POCT) [1]. - The company's revenue composition includes chronic disease testing (45.93%), infectious disease testing (30.93%), drug abuse testing (11.82%), pregnancy and reproductive health testing (11.27%), and other supplementary services (0.04%) [1]. Market Position - Wanfu Biological is classified under the pharmaceutical and biological industry, specifically in medical devices and in vitro diagnostics. The company is associated with various concept sectors, including avian influenza drugs, assisted reproduction, anti-influenza, gene sequencing, and the pet economy [1].

Group 1: Company Overview and AI Medical Layout - Guangzhou Wanfu Biological Technology Co., Ltd. has been investing in AI medical since 2018, aiming to become a leading enterprise in the domestic AI medical field through a "merger + hospital end + consumer end" strategy [2][4] - The company’s investment in Saiweisen Medical Technology led to the first domestic Class III medical device registration for cervical cancer cell digital pathology software in February 2025 [2][3] - Wanfu has developed the "Wanfu Smart Inspection" AI platform for hospitals, which has been implemented in various medical scenarios [3][4] Group 2: Investment and Collaboration - The company collaborates with Saiweisen, Shengqiang, and Yizhun Intelligent to enhance diagnostic capabilities through software and hardware integration [4][5] - The partnership aims to leverage each company's strengths in imaging, pathology, and laboratory testing to capture opportunities in AI applications [4][5] Group 3: Product Development and Market Position - Saiweisen has received the first Class III certification for AI-assisted diagnosis in gynecology, with ongoing clinical trials for non-gynecological applications [5][6] - Shengqiang Technology has developed a comprehensive digital pathology solution, covering approximately 2,000 hospitals domestically and 12 overseas regions [7][8] - Yizhun Intelligent holds 15 Class II and 6 Class III certifications, with a focus on ultrasound AI technology, which is more complex than radiology AI [9][10] Group 4: Market Trends and Future Outlook - The introduction of new policies is expected to significantly increase the volume of digital slices in the pathology market, creating substantial market capacity [8][9] - The AI medical sector is projected to grow rapidly, with a focus on enhancing brand influence and operational efficiency through innovative AI applications [10][11] - The company anticipates a recovery in domestic business in 2026, supported by overseas growth driven by various platforms [12][13]

Summary of Wanfu Biological Conference Call Company Overview - **Company**: Wanfu Biological - **Industry**: AI Medical Technology and Digital Pathology Key Points and Arguments Investment and Development in AI Medical Technology - Wanfu Biological has invested in multiple companies including Saiweisen, Senqiang Technology, and Yizhun Intelligent, establishing a multimodal diagnostic framework in digital pathology and AI imaging, leading to the commercialization of AI in healthcare [2][3] - Saiweisen has achieved a leading position in pathology-assisted diagnosis, receiving the first Class III certification for cervical cytology AI software in China, implemented in over 100 medical institutions domestically and internationally [2][3] - Senqiang Technology focuses on digital pathology solutions, covering approximately 2,000 hospitals in China and 12 overseas regions, enhancing hospital workflow through hardware and intelligent software [2][6] - Yizhun Intelligent has strong competitiveness in AI imaging and ultrasound imaging, with its breast X-ray and thyroid nodule ultrasound detection software receiving the first and second Class III certifications in the industry [2][7] Market Growth and Financial Projections - Wanfu Biological expects rapid growth in domestic business in 2026, with a year-on-year growth rate exceeding 40%, and overseas business growth projected between 20% and 30% [3][29] - Core revenue is anticipated to grow by 30% year-on-year, with a profit margin target of over 20% [3][29] - Senqiang Technology forecasts sales revenue between 250 million to 300 million yuan in 2026, driven by new policies and increased overseas revenue [3][21] AI Medical Ecosystem and Future Directions - The company has built an AI medical ecosystem since 2018, combining acquisitions and internal growth, focusing on both hospital and consumer segments [3][12] - Future trends include multi-omics and multimodal diagnostics, with a strong emphasis on enhancing brand influence and operational efficiency through AI applications [13][31] Challenges and Strategic Adjustments - Wanfu Biological's performance forecast for 2025 indicates pressure due to the overall IVD industry challenges, prompting strategic adjustments such as inventory reduction and risk asset divestment [28][29] - The company has achieved significant operating cash flow, with a net cash flow of nearly 400 million yuan in 2025, indicating resilience despite challenges [29] Collaboration and Synergy - Collaboration with invested companies like Saiweisen and Senqiang Technology is crucial for market expansion and technological upgrades, enhancing the overall business ecosystem [3][21][22] AI Product Development and Market Position - Yizhun Intelligent holds six Class III certifications for AI products, demonstrating its leadership in the field and commitment to rapid commercialization [11][22] - The company aims to increase the paid hospital ratio for its AI products to 80%-90% and enhance repeat purchase rates across multiple disease categories [11] Regulatory and Market Dynamics - The digital pathology sector is rapidly evolving, with significant policy changes creating a market capacity of 5 billion yuan due to new regulations on slide uploads [9][10] - Saiweisen's dual sales model includes traditional software sales and SaaS subscription services, adapting to different market needs [15][19] Additional Important Insights - The digital pathology solutions market is characterized by a shift towards automation and standardization, with Senqiang Technology leading in comprehensive digital pathology solutions [8][9] - The AI medical field is seen as a critical area for future growth, with Wanfu Biological committed to enhancing its capabilities and market presence through strategic investments and partnerships [31][32]

Core Viewpoint - The performance decline of Wanfu Biological is attributed to the dual constraints of centralized procurement and industry regulations in the IVD sector, significantly impacting pricing and sales volume [1][13][17]. Financial Performance - Wanfu Biological's 2025 earnings forecast indicates a net profit of 46 million to 69 million yuan, representing a year-on-year decline of 87.71% to 91.81% [1][14]. - For the first three quarters of 2025, the company reported a main revenue of 1.69 billion yuan, down 22.52% year-on-year, and a net profit of 134 million yuan, down 69.32% [2][15]. - The third quarter alone saw a main revenue of 445 million yuan, a decline of 26.66% year-on-year, with a net loss of approximately 55.46 million yuan [2][15]. Market Conditions - The IVD market in China experienced a 5.9% decline in size during the first three quarters of 2025, with the biochemical and immunological sectors showing the most significant downturn [20]. - The A-share IVD sector reported total revenue of 27.62 billion yuan, down 14.5% year-on-year, and a net profit of 4.49 billion yuan, down 26.4% [20]. Pricing and Procurement Impact - The IVD industry is facing significant price pressure due to centralized procurement, with some product prices dropping by over 70% [17]. - As of 2024, five rounds of provincial alliance centralized procurement have been completed, covering core products and regions [17]. Regulatory Environment - New policies from the National Health Commission aim to standardize inspection and testing results across medical institutions, which may further impact sales volumes by reducing unnecessary repeat tests [5][19]. - The "minimum necessary" principle has been emphasized in recent regulations, mandating a review of clinical necessity for various testing projects [6][19]. Accounts Receivable Concerns - Wanfu Biological's accounts receivable have surged, with turnover days increasing from 32 days in 2022 to 172 days in 2023, raising concerns about potential impairment risks [12][22]. - As of the last report, accounts receivable amounted to 1.046 billion yuan, accounting for approximately 60% of the company's revenue [22]. Business Segmentation - Chronic disease detection is the largest business segment for Wanfu Biological, contributing 44.66% of revenue, while infectious disease detection accounts for 34% [22][23]. - Both segments have seen significant revenue declines, with chronic disease management revenue dropping by 26.06% and infectious disease revenue by 21.14% year-on-year [22]. Future Outlook - The impact of centralized procurement is expected to persist until 2026, with ongoing challenges anticipated for Wanfu Biological's performance [1][21]. - The company is focusing on stabilizing its overseas business, which is seen as a crucial support for sustainable growth [25].